Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RL-MT in First-line PCNSL
NCT04737889Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in primary central nervous system lymphoma (PCNSL), sponsored by Henan Cancer Hospital. Started Jan 2021; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04737889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737889.